If you have been reading about clinical endpoint and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-03-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
| Property | Value | Notes |
|---|---|---|
| First described | 1977 | Reported as a component of thymosin fraction 5 |
| Sequence length | 28 amino acids | N-terminal residue is acetylated |
| Net charge at neutral pH | Negative | Reflects a high proportion of acidic residues |
| Principal studied uses | Chronic hepatitis B and vaccine adjuvant | Research uses outnumber approved indications |
| Regulatory status | Approved in a limited number of countries | Not approved in the United States or most of Europe |
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Stability depends on temperature, pH, and the number of freeze-thaw events the sample has experienced. Freeze-dried material is commonly held at -20 °C or colder, while reconstituted liquid is kept cold and used within a short window. Extreme pH and prolonged light exposure can promote deamidation, oxidation, or aggregation, particularly at asparagine and methionine positions. Adsorption to container walls can lower the measured concentration of a dilute solution even when the peptide molecules themselves remain intact.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or chemically modified byproducts. Mass spectrometry confirms the expected molecular mass and can indicate acetylation state or sequence errors. Amino acid analysis and peptide mapping supply complementary sequence-level information, while endotoxin testing is relevant for preparations intended for cell or animal work. Purity figures reported by suppliers refer to the method used and are not directly comparable across laboratories unless conditions are stated.
==== VPS35 ==== VPS35 (PARK17, MEM3) is involved in cellular transport mechanisms such as endosomal trafficking, the sorting and recycling of proteins in the cell. Such recycling is essential to normal cell functioning. Normally VPS35 regulates the sorting and transport of proteins controlling mitochondrial fusion and fission. Absence or mutation of VPS35 can cause mitochondrial fragmentation, the accumulation of damaged mitochondria within the cell, and impaired function. The VPS35 D620N mutant further interferes with the activity of PINK1 and PRKN in recycling damaged mitochondria. VPS35 mutations are related to a number of diseases that involve disruptions of normal mitochondrial and retromer activity, including PD. VPS35-related PD is extremely rare.
A case of major potassium depletion has been attributed to chronic licorice ingestion, and consequently professional herbalists avoid the use of licorice where they recognize that this may be a risk. Black cohosh has been implicated in a case of liver failure. Few studies are available on the safety of herbs for pregnant women, and one study found that use of complementary and alternative medicines is associated with a 30% lower ongoing pregnancy and live birth rate during fertility treatment. Examples of herbal treatments with likely cause-effect relationships with adverse events include aconite (which is often a legally restricted herb), Ayurvedic remedies, broom, chaparral, Chinese herb mixtures, comfrey, herbs containing certain flavonoids, germander, guar gum, liquorice root, and pennyroyal. Examples of herbs that may have long-term adverse effects include ginseng, the endangered herb goldenseal, milk thistle, senna, aloe vera juice, buckthorn bark and berry, cascara sagrada bark, saw palmetto, valerian, kava (which is banned in the European Union), St. John's wort, khat, betel nut, the restricted herb ephedra, and guarana. There is also concern with respect to the numerous well-established interactions of herbs and drugs.
=== Biscuits company === In 1938, Lyons purchased the Bee Bee Biscuit Company, which manufactured biscuits from its factories in Blackpool. Six years later, Lyons changed the company's name to Symbol Biscuits Ltd. and began selling biscuits under the Symbol and Lyons brand names: one of their innovations was Maryland Cookies in 1956. In 1990, Lyons changed the Symbol Biscuits name to Lyons Biscuits Ltd.
== Personnel == Fishbone Angelo Moore – saxophone, vocals Walter A. Kibby II – trumpet, vocals Kendall Jones – guitars, vocals Chris Dowd – keyboards, trombone, vocals John Norwood Fisher – bass, vocals Philip "Fish" Fisher – drums Additional personnel Lisa Grant – vocals on "Lyin' Ass Bitch" Production Nancy Donald – design David Kahne – engineer Tony Lane – design David Leonard – engineer, mixing John Scarpati – photography Jack Skinner – mastering (Sterling Sound, New York City)
Sources: en.wikipedia.org
== Instant tea == In 1946, Nestle USA introduced the first instant tea, Nestea. Instant teas are produced from black tea by extracting the liquor from processed portion of tea typically from offgrade black teas; green tea in a smaller proportion has traditionally been used by the instant tea makers as a "clarification agent" - again, in effort to maximize the clarity of color and minimize off-colors created by certain teas that cloud. The extract is concentrated under low pressure, and drying the concentrate to a powder by freeze-drying, spray-drying, or vacuum-drying. Low temperatures tend to be used to minimize loss of flavor. The American market for instant tea powders, which developed quickly following Nestle's introduction, has slackened off considerably over the past quarter century, as Americans have more and more turned to naturally icing their favorite loose teas, as well as preparing iced tea from tea bags, and to ready-to-drink iced teas where the smaller sizes are found in the supermarkets' refrigerated drinks sections and the larger gallon sizes are found in the supermarkets' non-refrigerated drinks sections.
=== Australia === In-N-Out Burger has also had other similarly named imitators in Australia that confuse consumers into thinking that the businesses is associated with the Californian-based chain. The company would take the imitators to court for trademark infringement and has opened one-day pop-ups in Sydney in 2012, 2013, 2016, 2017, 2019, and 2022; Brisbane in 2020; Melbourne in 2014 and 2018; and Perth in 2018 and 2022 to preserve their trademark rights. Customers may wait for several hours before the doors open, but the food would run out very quickly, sometimes in less than hour after opening. Although In-N-Out may not have plans to open a permanent location outside its current operating region, the business strategy of having one-day pop-ups is to maintain a business presence in the country under Australian trademark law without opening a permanent restaurant. In-N-Out successfully defended their trademarks and intellectual property rights in Australia in 2020 against Hashtag Burgers Pty Ltd, formerly doing business as "Funk N Burgers" and "Down-N-Out Burger". In 2021, In-N-Out filed a lawsuit against Queensland-based Rich Asians Pty Ltd doing business as "In & Out Aussie Burgers".
== Challenges and future outlook == The commercial viability of Pakistan’s oil potential remains uncertain, constrained by geopolitical volatility, investor hesitation, and logistical hurdles. Governance remains a concern—including equitable integration of provincial stakeholders and transparency in licensing. There is anticipation for the first shipment of U.S. crude oil to Pakistan, likely in October 2025 via Cnergyico and Vitol, symbolizing the deal's early implementation. The potential of exports to India remains speculative, heavily contingent on regional diplomacy and stability.
In Warwick 1816, a farm laborer was tried and convicted of the murder of a young maidservant. She had been drowned in a shallow pool and bore the marks of violent assault. The police found footprints and an impression from corduroy cloth with a sewn patch in the damp earth near the pool. There were also scattered grains of wheat and chaff. The breeches of a farm labourer who had been threshing wheat nearby were examined and corresponded exactly to the impression in the earth near the pool. An article appearing in Scientific American in 1885 describes the use of microscopy to distinguish between the blood of two persons in a criminal case in Chicago.
=== Augusta National green jacket === The green jacket is reserved for Augusta National members and golfers who win the Masters Tournament. Jackets are kept on club grounds, and taking them off the premises is forbidden. The exception is for the winner, who can take it home and return it to the club the following year. Player, who became the tournament's first international winner in 1961, said he did not know that, he packed the jacket and took it to his home in South Africa. That led to a call from club Chairman Clifford Roberts, who was a stickler for rules. "I didn't know you were supposed to leave it there," Player said. "Next thing you know, there was a call from Mr. Roberts."
Sources: en.wikipedia.org
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.
Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.